Vinge has advised Vicore Pharma Holding AB (publ) in connection with two directed share issues totaling at SEK 64 million through a private placement procedure.

Two directed share issues were resolved upon, one pursuant to authorization from the general annual meeting in 2016 comprising two million shares and a second subject to approval by the extraordinary shareholders’ meeting comprising one and a half million shares. Both share issues were directed to an international healthcare specialist investor together with several Swedish institutional investors. The subscription price was determined to SEK 16 per share.

Vicore Pharma is listed on Nasdaq Stockholm First North and develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company’s lead candidate, C21 is being developed for the indication Idiopatic pulmonary fibrosis (IPF).

Vinge’s team consisted of Jesper Schönbeck and Sabina Börjesson.